V
Verena Wagner
Researcher at Imperial College London
Publications - 11
Citations - 216
Verena Wagner is an academic researcher from Imperial College London. The author has contributed to research in topics: Senescence & Multiple myeloma. The author has an hindex of 5, co-authored 11 publications receiving 115 citations. Previous affiliations of Verena Wagner include German Cancer Research Center & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb,Nicolás Herranz,Sara Arce-Gallego,Susana Miranda,Lorenzo Buroni,Wei Yuan,Alejandro Athie,Teresa Casals,J. Carmichael,J. Carmichael,Daniel Nava Rodrigues,Bora Gurel,Pasquale Rescigno,Pasquale Rescigno,Jan Rekowski,Jon Welti,Ruth Riisnaes,Veronica Gil,Jian Ning,Verena Wagner,Irene Casanova-Salas,Sarai Cordoba,Natalia Castro,Maria de Los Dolores Fenor de la Maza,Maria de Los Dolores Fenor de la Maza,George Seed,Khobe Chandran,Khobe Chandran,Ana Ferreira,Ines Figueiredo,Claudia Bertan,Diletta Bianchini,Diletta Bianchini,Caterina Aversa,Caterina Aversa,Alec Paschalis,Alec Paschalis,Macarena Gonzalez,Rafael Morales-Barrera,Cristina Suarez,Joan Carles,Amanda Swain,Adam Sharp,Adam Sharp,Jesús Gil,Violeta Serra,Christopher J. Lord,Suzanne Carreira,Joaquin Mateo,Johann S. de Bono,Johann S. de Bono +50 more
TL;DR: This data indicates that ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition.
Journal ArticleDOI
Senescence as a therapeutically relevant response to CDK4/6 inhibitors.
Verena Wagner,Jesús Gil +1 more
TL;DR: This review analyzes the therapeutic relevance of senescence induction by CDK4/6 inhibitors and discusses how different therapies, including checkpoint inhibitors and drugs targeting MEK or PI3K, can be used in combination with CDK6 inhibitors to reinforce or exploit senescences.
Journal ArticleDOI
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia
Naveen Pemmaraju,Dhaval Shah,Hagop M. Kantarjian,Robert Z. Orlowski,Graciela M. Nogueras González,Veera Baladandayuthapani,Nitin Jain,Verena Wagner,Guillermo Garcia-Manero,Jatin P. Shah,Farhad Ravandi,Sherry Pierce,Koichi Takahashi,Naval Daver,Aziz Nazha,Srdan Verstovsek,Elias Jabbour,Marcos de Lima,Richard E. Champlin,Jorge E. Cortes,Muzaffar H. Qazilbash +20 more
TL;DR: The development of t-MN in patients with multiple myeloma is associated with poor outcomes, and these patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times.
Journal ArticleDOI
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
Verena Wagner,Dirk Hose,Anja Seckinger,Ludmila Weiz,Tobias Meißner,Thiery Rème,Iris Breitkreutz,Klaus Podar,Anthony D. Ho,Hartmut Goldschmidt,Alwin Krämer,Bernard Klein,Marc S. Raab +12 more
TL;DR: Gene expression and protein profiling revealed the critical roles of IL6/STAT3-signaling and the unfolded protein response in the efficacy of YM155, and down regulate anti-apoptotic Mcl-1 in myeloma cells.
Journal ArticleDOI
Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications
Verena Wagner,Dirk Hose,Anja Seckinger,Ludmila Weitz,Tobias Meißner,Thierry Rème,Jean-François Rossi,Hartmut Goldschmidt,Alwin Krämer,Bernard Klein,Marc S. Raab +10 more
TL;DR: The expression of survivin is determined in CD138-purified multiple myeloma cells from previously untreated patients at the centers9 trial group (TG) (n=246) and the UAMS Arkansas validation group (VG) using the PANP algorithm.